Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Infections

Infections

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Infections

66 trials tracked for Infections: 21 in phase 3 or 4 and 6 with published results. The most-cited published study has 44 citations.

66Trials tracked
21Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 6 Phase 3 15 Phase 2 7 Phase 1 5 Other / NA 33
  1. Phase 4 Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization Completed · 44 cited
  2. Phase 3 Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Completed · 42 cited
  3. Phase 3 Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) Completed · 34 cited
  4. Phase 4 Antibiotic Prophylaxis for Transrectal Prostate Biopsy Completed · 21 cited
  5. Phase 4 Prophylaxis of Periprosthetic Joint Infections With Calcium Sulfate Beads in Patients With Non-modifiable Risk Factors. Completed · 11 cited
  6. Phase 3 Topical Vancomycin for Neurosurgery Wound Prophylaxis Completed · 9 cited
Show 44 more trials
  1. Phase 4 Probiotics to Promote Intestinal Health Completed
  2. Phase 4 Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus Completed
  3. Phase 4 A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections Completed
  4. Phase 3 Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery Completed
  5. Phase 3 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers Completed
  6. Phase 3 Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers Completed
  7. Phase 3 Study of Antimicrobial Activity of Omiganan 1% Gel vs. Chlorhexidine 2% for Topical Skin Antisepsis in Healthy Adult Subjects Completed
  8. Phase 3 Efficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056) Completed
  9. Phase 3 Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections Completed
  10. Phase 3 Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy Completed
  11. Phase 3 Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study) Completed
  12. Phase 3 Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters Completed
  13. Phase 3 Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101) Completed
  14. Phase 3 Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem Completed
  15. Phase 3 Efficacy and Safety of Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Transplant Recipients Avoiding Intraoperative Steroids Completed
  16. Phase 2 Daptomycin in Treating Neutropenia and Fever in Patients With Cancer Completed
  17. Phase 2 Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients Completed
  18. Phase 2 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed
  19. Phase 2 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed Completed
  20. Phase 2 Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Completed
  21. Phase 2 Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients Completed
  22. Phase 2 Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection Completed
  23. Phase 1 The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery Completed
  24. Phase 1 Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum Completed
  25. Phase 1 Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age Completed
  26. Phase 1 Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults Completed
  27. Phase 1 Pharmacokinetics of Ceftaroline in Subjects 12 to 17 Years of Age Completed
  28. N/A Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy Completed
  29. N/A Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care Completed
  30. N/A RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction Completed
  31. N/A Reducing Aerosol and Bioaerosol Using Different Oral Suctions Completed
  32. N/A Impact of Chlorhexidine Cleansing on Bacteria Colonizing the Umbilical Cord of Infants in Bangladesh Completed
  33. N/A Cerebrospinal Fluid (CSF) Pharmacokinetics of Antimicrobials in Children Completed
  34. N/A Antibiotic Irrigation for Pancreatoduodenectomy Completed
  35. N/A Extracardiac Complications After Cardiac Surgery Completed
  36. N/A Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM) Completed
  37. N/A Impact of Clinical Guidance & Point-of-care CRP in Children: the ARON Project Completed
  38. N/A Is Iron Deficiency the Cause of Anemia Among Women in Cambodia? Completed
  39. N/A A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting Completed
  40. N/A Understanding Childhood Infection, Inflammation and Allergy Completed
  41. N/A Community Central Line Infection Prevention Trial Completed
  42. N/A Paediatric Rapid Sepsis Trigger (PRST) Tool Completed
  43. N/A Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis Completed
  44. N/A Targeted Infection Control in Long-term Care Completed

Showing the 50 most-cited and recently-updated of 66 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Infections: what the trials found

Several interventions have been evaluated for infection management and prophylaxis. Local antibiotic delivery via a medicated calcium sulfate bead system significantly reduced periprosthetic joint infection rates compared to conventional intravenous prophylaxis (p < 0.05) and was associated with shorter hospital stays (p < 0.01). Gentamicin-loaded collagen sponges demonstrated clinical superiority in ulcer closure rates (67% vs 32% vs 29%) and lower reinfection rates compared to other treatments 13, while also showing higher clinical cure rates than some alternatives 12.

Pharmacological trials for infection control show mixed results. Ciprofloxacin was evaluated but did not significantly differ in the proportion of patients experiencing serious bacterial infections (p = 0.218) 16. Standard antimicrobial therapy showed no significant difference in microbial response, graft-versus-host disease incidence, or long-term survival compared to other protocols 17. Fluconazole was evaluated for fungal prophylaxis, showing a 74.9% to 78.2% fungal-free survival rate at 180 days post-transplant 15.

Other studied agents include ertapenem sodium, which showed high rates of successful prophylaxis (over 90%) and favorable clinical response (over 95%) 18, and Daptomycin 19. A study on Plerixafor showed no significant difference in total infection severity scores (p = 0.65) 9. Additionally, omiganan 1% gel significantly reduced skin bacterial counts from baseline to 72 hours (p < 0.001) 22.

Recent results — preliminary, needs further review

  • The H5N6c vaccine showed a mean geometric mean fold increase in HI antibodies of up to 12.13, with seroconversion rates reaching 37.3% 1.
  • The strip Peri Screen was evaluated in a recent study 2.

For the clinician treating this condition

  • Gentamicin collagen sponges are associated with superior ulcer closure and lower reinfection rates compared to alternative treatments.
  • Medicated calcium sulfate beads for local antibiotic prophylaxis significantly reduce periprosthetic joint infection rates and hospital stay duration.
  • Fluconazole provides high fungal-free survival rates (approx. 75-78%) in post-transplant patients.

AI synthesis of 11 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review details metabolic adaptations of intracellular bacterial pathogens within host cells
Infectious Disease Sys. Review
Systematic review details metabolic adaptations of intracellular bacterial pathogens within host cells How do bacteria hide inside our cells to survive and cause disease?
A systematic review synthesized evidence on how intracellular bacterial pathogens, including Listeria and Chlamydia species, employ sophisti…
Bacteria like Listeria and Chlamydia act as metabolic thieves, stealing nutrients from our cells to hide from our immune system and survive.
Frontiers Apr 1, 2026

Questions about Infections

Does getting enough antibiotics help patients with infections leave the hospital sooner?

Getting enough appropriate antibiotics significantly shortens hospital stays for infections, with adequate therapy reducing average stay by about 1.2 days compared to inadequate treatment.

Full answer →
Can high bilirubin levels and infections cause hearing loss in newborns in the NICU?

Yes, high bilirubin levels and certain infections like cytomegalovirus are established risk factors for hearing loss in newborns in the NICU.

Full answer →
How does adequate antibiotic therapy affect hospital length of stay for infections?

Adequate antibiotic therapy significantly shortens hospital stays for infections, reducing the average length of stay by about 1.17 days compared to inadequate treatment.

Full answer →